Log in

Entasis Therapeutics Stock Price, News & Analysis (NASDAQ:ETTX)

$5.75
-0.05 (-0.86 %)
(As of 10/20/2019 01:00 PM ET)
Today's Range
$5.76
Now: $5.75
$5.91
50-Day Range
$5.52
MA: $6.23
$7.71
52-Week Range
$3.97
Now: $5.75
$9.25
Volume716 shs
Average Volume19,441 shs
Market Capitalization$75.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETTX
CUSIPN/A
CIKN/A
Phone781-810-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5 million
Book Value$6.33 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$75.56 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.


Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) announced its quarterly earnings data on Monday, August, 12th. The company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.44. View Entasis Therapeutics' Earnings History.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Entasis Therapeutics.

What price target have analysts set for ETTX?

5 brokerages have issued 1-year target prices for Entasis Therapeutics' stock. Their forecasts range from $18.00 to $20.00. On average, they expect Entasis Therapeutics' share price to reach $18.60 in the next twelve months. This suggests a possible upside of 223.5% from the stock's current price. View Analyst Price Targets for Entasis Therapeutics.

What is the consensus analysts' recommendation for Entasis Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Entasis Therapeutics.

Has Entasis Therapeutics been receiving favorable news coverage?

Headlines about ETTX stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Entasis Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Entasis Therapeutics.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 45,500 shares, an increase of 27.8% from the August 30th total of 35,600 shares. Based on an average daily volume of 18,700 shares, the short-interest ratio is presently 2.4 days. Currently, 1.9% of the shares of the company are short sold. View Entasis Therapeutics' Current Options Chain.

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the folowing people:
  • Manoussos Perros, President, Chief Executive Officer & Director
  • Mike Gutch, Chief Financial Officer & Chief Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • Robin Isaacs, Chief Medical Officer
  • John Mueller, Chief Development Officer

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an IPO on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $5.75.

How big of a company is Entasis Therapeutics?

Entasis Therapeutics has a market capitalization of $75.56 million and generates $5 million in revenue each year. The company earns $-32,950,000.00 in net income (profit) each year or ($12.31) on an earnings per share basis. View Additional Information About Entasis Therapeutics.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is http://www.entasistx.com/.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at 781-810-0120 or via email at [email protected]


MarketBeat Community Rating for Entasis Therapeutics (NASDAQ ETTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Entasis Therapeutics and other stocks. Vote "Outperform" if you believe ETTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: What is the Coverage Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel